HIGHLIGHTS
- who: Qingfang Li from the Oncothyreon Canada have published the Article: Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy, in the Journal: (JOURNAL)
- what: Both the PI3K/AKT/mTOR and RAF/MEK/ERK pathways are frequently involved in cancer therapy.
- how: These results showed that these two pathways serve as a complex network and provide a method for dual therapeutic compounds that can simultaneously block both pathways . In a phase II study of copanlisib in various lymphomas the results showed that intravenous copanlisib could offer promising efficacy and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.